BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8033045)

  • 1. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma.
    Baker TR; Piver MS; Hempling RE
    Cancer; 1994 Jul; 74(2):656-63. PubMed ID: 8033045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of serum CA125 following optimal cytoreductive surgery during weekly cisplatin induction therapy for advanced ovarian cancer.
    Hempling RE; Piver MS; Natarajan N; Baker TR; Thompson JM; Hicks ML; Mettlin CJ
    J Surg Oncol; 1993 Sep; 54(1):38-44. PubMed ID: 8377503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
    Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
    Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Tsukada Y; Emrich LJ
    J Clin Oncol; 1988 Jun; 6(6):983-9. PubMed ID: 3373267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Eur J Gynaecol Oncol; 1998; 19(1):5-10. PubMed ID: 9476049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
    Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
    Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
    Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
    Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
    Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
    Li M; Huang X
    Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
    Yamamoto K; Oogi S; Inoue H; Kudoh K; Kita T; Kikuchi Y
    Curr Med Chem; 2004 Feb; 11(4):425-8. PubMed ID: 14965223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
    Morris M; Gershenson DM; Burke TW; Kavanagh JJ; Silva EG; Wharton JT
    Obstet Gynecol; 1990 Dec; 76(6):1020-4. PubMed ID: 2234710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
    Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
    J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
    Isonishi S; Niimi S; Sasaki H; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Jun; 93(3):647-52. PubMed ID: 15196859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance of clinically prognostic factors in the treatment of advanced ovarian carcinoma].
    Albrecht M; Goepel E; Simon WE; Trams G
    Geburtshilfe Frauenheilkd; 1985 Jul; 45(7):482-7. PubMed ID: 2993094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.